Dr.Reddy's Laboratories Ltd (REDY.NS)
** Delay in monetisation of key drugs such as Nexium and Copaxone, which implies low-teen FY16 EPS growth - Credit Suisse
** Dr.Reddy's Laboratories shares fall 1.2 pct ** Canadian importers agree to quarantine products from Dr.Reddy's Srikakulam plant and Ipca Laboratories' Pithampur facility, Health Canada says (http://bit.ly/1HyUTK4) ** Quarantine request due to data integrity concerns, Canadian drug regulator adds ** Continued concerns that sales in Russia may be impacted due to brewing financial crisis in the region also weigh (Reuters Messaging: firstname.lastname@example.org)
Shares of India's Dr Reddy's Laboratories gain 0.9 percent.
* Shares of India's Dr Reddy's Laboratories gain 0.9 percent. * Morgan Stanley upgrades the stock to "overweight" from "equal-weight"; raises price target to 3,875 rupees from 3,049 rupees. * Says drugmaker's U.S. pipeline outlook has strengthened and valuations appears to be reasonable. * "We expect a better outlook for FY16 and FY17 as underlined by improving India, and US businesses," it said. (email@example.com/indulal.p.thomsonreuters.com@reut ers.net)
Reuters Market Eye - Shares in Dr.Reddy's Laboratories gain 1.58 percent vs a 0.02 percent fall in the Nifty.
* Shares in India's Dr.Reddy's Laboratories gain 1.1 percent vs a 0.2 percent fall in the NSE index. * A filing with the U.S. Securities and Exchange Commission on Monday shows market share gains in key drugs in the U.S. market, analysts say. (http://1.usa.gov/1tk9u78) (firstname.lastname@example.org / email@example.com)